MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jad.2009.06.041

Медицинская библиотека · Journal of affective disorders · 2009

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

Lam Raymond W, Kennedy Sidney H, Grigoriadis Sophie, McIntyre Roger S, Milev Roumen, Ramasubbu Rajamannar, Parikh Sagar V, Patten Scott B, Ravindran Arun V, Canadian Network for Mood and Anxiety Treatments (CANMAT)

СтатьяКлинические рекомендацииПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field.

METHODS

The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included Levels of Evidence and expert clinical support. This section on "Pharmacotherapy" is one of 5 guideline articles.

RESULTS

Despite emerging data on efficacy and tolerability differences amongst newer antidepressants, variability in patient response precludes identification of specific first choice medications for all patients. All second-generation antidepressants have Level 1 evidence to support efficacy and tolerability and most are considered first-line treatments for MDD. First-generation tricyclic and monoamine oxidase inhibitor antidepressants are not the focus of these guidelines but generally are considered second- or third-line treatments. For inadequate or incomplete response, there is Level 1 evidence for switching strategies and for add-on strategies including lithium and atypical antipsychotics.

LIMITATIONS: Most of the evidence is based on trials for registration and may not reflect real-world effectiveness.

CONCLUSIONS

Second-generation antidepressants are safe, effective and well tolerated treatments for MDD in adults. Evidence-based switching and add-on strategies can be used to optimize response in MDD that is inadequately responsive to monotherapy.

Для цитирования: Lam Raymond W, Kennedy Sidney H, Grigoriadis Sophie, McIntyre Roger S, Milev Roumen, Ramasubbu Rajamannar, Parikh Sagar V, Patten Scott B, Ravindran Arun V, Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.. Journal of affective disorders. 2009. DOI: 10.1016/j.jad.2009.06.041.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.